Ipsen is paying $247 million to acquire Epizyme, a cancer drug developer with one FDA-approved product: follicular lymphoma therapy Tazverik. The drug is a modest seller now, but more cash could be paid out if the small molecule hits sales targets in coming years.
The company said the FDA had accepted its application for accelerated approval of Tazverik in relapsed/refractory follicular lymphoma. The drug won accelerated approval last month for epithelioid sarcoma.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The agency gave accelerated approval to Tazverik in epithelioid sarcoma, a rare but serious connective tissue cancer. The company is also seeking approval for the drug, an EZH2 inhibitor, for the blood cancer follicular lymphoma.
The agency's Oncologic Drugs Advisory Committee voted unanimously to recommend approval of tazemetostat for epithelioid sarcoma. The company has said it would likely use drugs like Bristol-Myers Squibb's Revlimid as a benchmark for pricing.
The company said Thursday the agency had accepted its accelerated approval application for tazemetostat in epithelioid sarcoma. An analyst wrote that an FDA advisory committee meeting is likely to happen in the fourth quarter.
The company plans to bring NGS to health systems lacking the ability to perform it internally.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.
There’s an evolutionary benefit to being a risk-taker: Our loincloth-adorned forebears needed, after all, a fearless leader to explore uncharted, food-filled territory. In today’s society, who possesses these genes? Biotech leaders simply must be among the carriers, argues Louis Garguilo of Outsourced Pharma. He writes: Who might express this risk-taking gene in our industry if not the […]
Taking a fresh approach with a metabolic pathway that spurs cancer growth, spanking-new Cambridge cancer drug startup Raze Therapeutics has just raised a $24 million Series A. The company’s already got strong venture and big pharma backing – this early round includes Atlas Ventures, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management and […]